iCardio.ai
Overview
iCardio.ai offers FDA-cleared AI software designed to automate and enhance echocardiographic interpretation. The platform provides solutions for automated measurements (EchoMeasure™), disease detection such as aortic stenosis (CardioVision™), and objective image quality assessment. It aims to assist clinicians, enterprises, and institutions by integrating AI into existing PACS and hardware systems.
Key functionalities include automated ejection fraction prediction, real-time feature extraction and navigation for edge devices, and precise measurement of LVOT and aortic diameters. iCardio.ai also offers tools like EchoCheck for tracking image quality and completeness, Quantitative tools for automated linear and volumetric measurements, Qualitative tools for structural heart disease detection, and EchoGPT for image-to-text ultrasound descriptions. The company leverages a vast database of over 200 million individual images to develop its machine learning algorithms.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Automated echocardiographic measurements (EchoMeasureu2122)
- Automated detection of aortic stenosis (CardioVisionu2122)
- Objective image quality assessment
- Automated Ejection Fraction prediction
- Real-time feature extraction and navigation for edge devices
- LVOT and Aortic Diameters measurement
- Automated echocardiogram reports
- EchoCheck: Track image quality, echo completeness, and perspective classification
- Quantitative tools for automated linear and volumetric measurements
- EchoGPT: Image-to-text AI tool for ultrasound description
Use Cases
- Automating echo reports for enterprises and PACS integration
- Assisting clinicians in detecting structural heart disease like aortic stenosis
- Helping institutions assess and improve image quality for IAC accreditation
- Enhancing diagnostic accuracy and efficiency in echocardiography workflows
- Enabling increased access to cardiac diagnostics, especially with handheld ultrasound (POCUS)
- Providing data for clinical validation and custom AI model development
What Physicians Need to Know
Leverage iCardio.ai's automated echocardiography analysis to significantly enhance workflow efficiency and reduce inter-reader variability in measurements. The FDA-cleared CardioVisionu2122 for Aortic Stenosis can serve as a valuable diagnostic aid for early and accurate detection, particularly in outpatient or primary care settings, potentially leading to more timely interventions. Utilize the automated reporting features and image quality assessment to streamline documentation and ensure consistent study quality. Consider the platform's ability to integrate with existing PACS and ultrasound hardware for a cohesive diagnostic ecosystem.
iCardio.ai emphasizes robust integration capabilities, offering a simple API for custom solutions. It currently integrates with PACS and various ultrasound hardware, including partnerships with GE Healthcare, UltraLinQ, SARC MedIQ, and Butterfly Network. Future integrations are planned to enhance intracardiac echocardiography capabilities through collaboration with Abbott.
Details
| Category | Cardiology AI, Radiology & Imaging AI |
| Pricing | Paid — $6,000-15,000/month base charge; $2-4/scan minimum. |
| Deployment | Cloud-based (secure cloud server) or on-premise server, integrated with PACS and hardware systems (e.g., UltraLinQ, GE Healthcare). |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated iCardio.ai received FDA 510(k) clearance for its EchoMeasure™ software in October 2024 and for its CardioVision™ software for interpretation of aortic stenosis on echocardiography on November 24, 2025. The CardioVision™ software also received FDA Breakthrough Device Designation on February 21, 2024. |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology, Radiology |
What the Web Says
iCardio.ai is a Los Angeles-based company that develops machine learning and deep learning algorithms for the analysis and automation of echocardiograms (heart ultrasounds). Their technology aims to improve diagnostic accuracy and efficiency in cardiac care by providing automated measurements, detecting conditions like aortic stenosis, and generating preliminary reports. iCardio.ai has received FDA 510(k) clearance for its AI software for echocardiography interpretation and Breakthrough Device Designation for its aortic stenosis detection tool.
Overall: PositiveStrengths
- Automated echocardiogram interpretation, leading to increased efficiency and reduced manual workload for clinicians.
- Improved accuracy and consistency in diagnosing cardiac conditions, such as severe aortic stenosis.
- Potential for earlier diagnosis and improved patient outcomes.
- Reduces healthcare disparities by providing a standardized, unbiased diagnostic tool deployable across various settings.
- Partnerships with major healthcare organizations and ultrasound vendors for broader accessibility and integration.
- FDA 510(k) clearance and Breakthrough Device Designation for key products.
Limitations
- Limited independent reviews from physicians, healthcare IT, and tech reviewers outside of company-published or partner-related content.
- No reviews found on G2 or Capterra specifically for iCardio.ai, though general AI review trends on these platforms suggest potential concerns about accuracy, ease of use, and comprehensive functionality for AI tools.
- Reddit discussions about AI in echocardiography raise questions about accuracy, training, trust in technology, and the potential impact on the role of echocardiographers.
- The technology, while advanced, is still evolving, and further research is needed to enhance its capabilities.
Based on reviews from: iCardio.ai, MedAxiom, Spark xyz, Becker's Hospital Review, Product Hunt, iCardio, NVIDIA Technical Blog, Reddit, GenAI Labs, G2, Capterra, Viz.ai
Last updated: 2026-07-19
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate iCardio.ai
Videos
Product demos, reviews, and walkthroughs for iCardio.ai.
AI in Action E492: Roman Sandler, Co-Founder and CTO at iCardio.ai
Alldus International
iCardioai | Joseph Sokol
TCA Venture Group
Roman Sandler, CTO & Co-founder of iCardio.ai 7-23-23
Becker Private Equity and Business Podcast
iCardio - Lightning Pitch
MedTech Innovator
Roman Sandler, CTO & Co-founder of iCardio.ai 7-23-23
Becker Business Minute Podcast
Digifit iCardio Review u2013 Still Good?
HelperMan
